ANAPTYSBIO, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Revenue | $10.0M | $16.7M | $17.6M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $29.4M | $15.4M | $17.3M |
| SG&A Expense | $9.3M | $4.3M | $3.6M |
| Operating Income | $-28.8M | $-3.0M | $-3.3M |
| Operating Margin | -287.8% | -18.1% | -18.9% |
| Interest Expense | $1.8M | $458.0K | $460.0K |
| Pretax Income | $-30.1M | $-4.3M | $-5.3M |
| Income Tax Expense | $0 | $0 | $139.0K |
| Net Income | $-30.1M | $-4.3M | $-5.4M |
| Net Margin | -300.7% | -25.5% | -30.8% |
| EPS (Basic) | $-1.52 | $-1.62 | $-2.12 |
| EPS (Diluted) | $-1.52 | $-1.62 | $-2.12 |
| Shares Outstanding (Basic) | 23.8M | 2.7M | — |
| Shares Outstanding (Diluted) | 23.8M | 2.7M | — |
| Dividends Per Share | — | — | — |